The CHMP’s positive opinion was supported by data obtained from a pivotal Phase II AReSVi-006 trial.
Sun Pharma says it's responding to increased pressure from the FDA following a plant inspection last August.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.